Resectable Well-Differentiated versus Dedifferentiated Liposarcomas: Two Different Diseases Possibly Requiring Different Treatment Approaches
- 9 April 2008
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 15 (6) , 1585-1593
- https://doi.org/10.1245/s10434-007-9805-x
Abstract
Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly. We hypothesized that WD and DD have distinct biological behaviors mandating different treatments. A prospective sarcoma database identified all primary/recurrent RPLS treated between 1996 and 2007: 77 DD (52%) and 58 WD (39.2%) patients were analyzed for recurrence rate, recurrence free survival (RFS), and overall survival (OS). At presentation, WD were mostly primary whereas DD were mostly recurrent (75.9% versus 58.4%; p = 0.04). A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001). Multivisceral resection was more common in DD versus WD (45.5% versus 31%; p = 0.01). Gross total resection rates were equivalent (WD: 86.2%; DD: 85.7%). Overall and local recurrence were higher in DD versus WD (82.2% versus 50% and 71.2% versus 46.3%; p < 0.0001). Only 3.7% WD recurred as high grade metastatic disease. Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001). RFS and OS (1, 2, and 5 year) were higher in WD than DD (80.3% versus 55.9%; 65.1% versus 34.1%; 41.9% versus 7.8%; p < 0.0001) and (98% versus 88.1%; 95.6% versus 71.9%; 92.1% versus 36.5%; p < 0.0001) respectively. WD and DD have distinct biological behaviors. Gross total resection is achievable in most WD; unlike DD, high-grade recurrence is uncommon. Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection. The biological behaviors of well-differentiated and dedifferentiated liposarcomas differ significantly. This article presents outcomes of two different surgical approaches that were implemented at the UTMDACC, treating these tumors as different disease entities.Keywords
This publication has 18 references indexed in Scilit:
- Primary malignant retroperitoneal tumors: Analysis of a single institutional experienceEuropean Journal of Surgical Oncology, 2007
- Retroperitoneal liposarcomas: Follow‐up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomasCancer, 2006
- Retroperitoneal sarcoma: 25 years of experience with aggressive surgical treatment at the Institute of Oncology, LjubljanaJournal of Surgical Oncology, 2005
- Surgical management of primary and recurrent retroperitoneal liposarcomaBritish Journal of Surgery, 2005
- Retroperitoneal soft tissue sarcomasCancer, 2004
- Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal LiposarcomaAnnals of Surgery, 2003
- Liposarcoma: New entities and evolving conceptsAnnals of Diagnostic Pathology, 2000
- Prognostic Factors Predictive of Survival for Truncal and Retroperitoneal Soft-Tissue SarcomaAnnals of Surgery, 1995
- Liposarcoma A study of 55 cases with a reassessment of its classificationThe American Journal of Surgical Pathology, 1979
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958